A2 Bio Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 124

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $80M

  • Investors
  • 15

A2 Bio General Information

Description

Developer of a cell therapy designed to cure cancer via tumor-specific targeting. The company engineers tumor cells that target the loss of genetic material in tumors through the selective killing of tumor cells while leaving normal cells unharmed, enabling physicians to revolutionize the treatment of solid tumors.

Contact Information

Website
www.a2bio.com
Formerly Known As
HLA-A2
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 30301 Agoura Road
  • Suite 210
  • Agoura Hills, CA 91301
  • United States
+1 (805)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 30301 Agoura Road
  • Suite 210
  • Agoura Hills, CA 91301
  • United States
+1 (805)

A2 Bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

A2 Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series C) 09-Jan-2025 $80M Completed Clinical Trials - Phase 1
5. Later Stage VC (Series B) 16-Dec-2022 Completed Pre-Clinical Trials
4. Early Stage VC (Series B) 05-Feb-2021 Completed Pre-Clinical Trials
3. Early Stage VC (Series B) 30-Sep-2020 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 05-Nov-2019 $57M $64.5M Completed Pre-Clinical Trials
1. Early Stage VC (Series A1) 01-Apr-2018 $7.5M $7.5M Completed Startup
To view A2 Bio’s complete valuation and funding history, request access »

A2 Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A-1 6,000,000 $0.000010 6% $1.25 $1.25 1x $1.25 1.59%
Series A 57,000,000 $0.000010 6% $1 $1 1x $1 15.06%
To view A2 Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

A2 Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a cell therapy designed to cure cancer via tumor-specific targeting. The company engineers tumor cells that
Drug Discovery
Agoura Hills, CA
124 As of 2025

Santa Monica, CA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

A2 Bio Competitors (42)

One of A2 Bio’s 42 competitors is Kite Pharma, a Formerly VC-backed company based in Santa Monica, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kite Pharma Formerly VC-backed Santa Monica, CA
Adicet Bio Formerly VC-backed Boston, MA
Genocea Biosciences Formerly VC-backed Cambridge, MA
RAPT Therapeutics Formerly VC-backed South San Francisco, CA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
You’re viewing 5 of 42 competitors. Get the full list »

A2 Bio Patents

A2 Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026226857-A1 Compositions and methods for treating blood cancers Pending 23-Apr-2025
WO-2026198474-A1 Universal allogenic transplant for treatment for cancer associated with loss of heterozygosity Pending 17-Mar-2025
WO-2026147809-A1 Compositions and methods for treating blood cancers Pending 31-Dec-2024
WO-2026060446-A1 Engineered interleukins and uses thereof Pending 16-Sep-2024
WO-2026030629-A1 Compositions and methods for treating cancers Pending 31-Jul-2024 C07K16/3007
To view A2 Bio’s complete patent history, request access »

A2 Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

A2 Bio Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
BCM Ventures Venture Capital Minority
Mana Ventures Venture Capital Minority
Merck & Co. Corporation Minority
S32 Venture Capital Minority
Schroders Asset Manager Minority
You’re viewing 5 of 15 investors. Get the full list »

A2 Bio FAQs

  • When was A2 Bio founded?

    A2 Bio was founded in 2017.

  • Where is A2 Bio headquartered?

    A2 Bio is headquartered in Agoura Hills, CA.

  • What is the size of A2 Bio?

    A2 Bio has 124 total employees.

  • What industry is A2 Bio in?

    A2 Bio’s primary industry is Drug Discovery.

  • Is A2 Bio a private or public company?

    A2 Bio is a Private company.

  • What is the current valuation of A2 Bio?

    The current valuation of A2 Bio is .

  • What is A2 Bio’s current revenue?

    The current revenue for A2 Bio is .

  • How much funding has A2 Bio raised over time?

    A2 Bio has raised $353M.

  • Who are A2 Bio’s investors?

    BCM Ventures, Mana Ventures, Merck & Co., S32, and Schroders are 5 of 15 investors who have invested in A2 Bio.

  • Who are A2 Bio’s competitors?

    Kite Pharma, Adicet Bio, Genocea Biosciences, RAPT Therapeutics, and Inovio Pharmaceuticals are some of the 42 competitors of A2 Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process